C-Peptide: The Crucial Diabetes Biomarker

Peptide Biomarkers

1:1 ratio

C-peptide is released in a 1:1 molar ratio with insulin but has a longer half-life and is not extracted by the liver, making it a more reliable measure of beta-cell function than insulin itself.

Vinay et al., Clin Med Insights Endocrinol Diabetes, 2026

Vinay et al., Clin Med Insights Endocrinol Diabetes, 2026

View as image

Every time a pancreatic beta cell releases insulin, it simultaneously releases an equal amount of a 31-amino-acid peptide called C-peptide. For decades, C-peptide was considered metabolic waste, a connecting peptide whose only purpose was holding the A and B chains of proinsulin together during biosynthesis. That view has changed. C-peptide is now recognized as the most reliable clinical measure of beta-cell function and a potential biologically active peptide in its own right.^[1]

Unlike BNP and NT-proBNP in heart failure or chromogranin A in neuroendocrine tumors, C-peptide occupies a dual role: it is both a diagnostic biomarker used daily in clinical medicine and a candidate therapeutic molecule for diabetic complications. This article examines both dimensions.

From Proinsulin to C-Peptide: The Biology

Insulin is synthesized as a single-chain precursor called proinsulin. In the beta cell's secretory granules, proinsulin is cleaved by the enzymes PC1/3 and PC2 into three pieces: the A chain and B chain of insulin (which are linked by disulfide bonds to form the active hormone) and the connecting peptide (C-peptide) that previously joined them. All three components are released into the bloodstream in equimolar amounts when the beta cell degranulates in response to glucose.

The pharmacokinetic properties of C-peptide make it superior to insulin for measuring beta-cell output. Insulin has a circulating half-life of only 4-5 minutes and undergoes significant first-pass extraction by the liver (approximately 50% is removed on first pass). C-peptide has a half-life of approximately 30 minutes and is not extracted by the liver, instead being cleared primarily by the kidneys at a relatively constant rate.^[1] These properties mean that a single C-peptide measurement more accurately reflects average insulin secretion than a single insulin measurement, which fluctuates rapidly.

A 2017 practical review by Leighton and colleagues summarized the available sampling methods: urinary C-peptide to creatinine ratio (non-invasive, integrates secretion over hours), fasting serum C-peptide (simple, widely available), and stimulated C-peptide (glucagon or mixed-meal tolerance test, more sensitive for residual beta-cell function).^[2]

Diagnostic Applications: What C-Peptide Tells Clinicians

Differentiating Diabetes Types

The most established clinical use of C-peptide is distinguishing type 1 from type 2 diabetes, a classification that directly determines treatment strategy. Maddaloni and colleagues (2022) published a comprehensive clinical perspective on C-peptide in diabetes diagnosis:^[3]

• Type 1 diabetes: Autoimmune destruction of beta cells leads to absolute insulin deficiency. C-peptide is low or undetectable (fasting C-peptide below 0.2 nmol/L or 0.6 ng/mL strongly suggests this diagnosis)
• Type 2 diabetes: Beta cells are present but dysfunctional, with variable insulin secretion against a background of insulin resistance. C-peptide is usually normal or elevated early in the disease, declining over years
• LADA (Latent Autoimmune Diabetes in Adults): Initially resembles type 2 but C-peptide progressively declines as autoimmune beta-cell destruction advances, often reclassifying the patient's diagnosis
• MODY (Maturity Onset Diabetes of the Young): Specific genetic mutations produce characteristic C-peptide patterns that can help guide genetic testing decisions

The diagnostic value is greatest in established diabetes where the initial presentation may have been ambiguous. At diagnosis, there can be substantial overlap between type 1 and type 2 C-peptide levels, particularly in adults. The discriminatory power increases with disease duration as type 1 patients lose beta cells completely while type 2 patients retain residual secretion.

Guiding Treatment Decisions

C-peptide levels inform therapy selection. A patient with undetectable C-peptide requires exogenous insulin and cannot be managed with oral agents alone. Conversely, preserved C-peptide in a patient labeled as type 1 may indicate LADA or MODY, potentially changing the therapeutic approach.^[2]

Kahn and colleagues (2026) demonstrated that different glucose-lowering medications produce differential longitudinal effects on C-peptide response, suggesting that serial C-peptide monitoring could help clinicians assess whether a chosen therapy is preserving or accelerating beta-cell decline.^[4]

Fan and colleagues (2025) showed that semaglutide treatment increased C-peptide levels in patients with type 2 diabetes, reflecting improved beta-cell function or reduced beta-cell stress under GLP-1 receptor agonist therapy.^[5] Whether this C-peptide increase translates to long-term beta-cell preservation or simply reflects reduced secretory demand remains an active research question.

Biomarker for Insulin Resistance

Khan and colleagues (2018) evaluated C-peptide as a screening biomarker for insulin resistance in both diabetic and non-diabetic individuals.^[6] Because C-peptide reflects endogenous insulin production without the confounding effect of hepatic extraction, elevated fasting C-peptide in a non-diabetic individual suggests compensatory hyperinsulinemia, an early sign of insulin resistance that precedes glucose abnormalities by years.

Beyond Biomarker: C-Peptide as a Biologically Active Molecule

The Neuropathy Clinical Trial

The most clinically advanced exploration of C-peptide as a therapeutic molecule was a 12-month randomized, double-blind, placebo-controlled trial by Wahren and colleagues (2016) published in Diabetes Care.^[7]

The study tested once-weekly subcutaneous injections of long-acting C-peptide (PEGylated to extend its half-life) in type 1 diabetes patients with peripheral neuropathy. The primary endpoint was sensory nerve conduction velocity.

Results:

• The primary endpoint was negative: sensory nerve conduction velocity did not improve versus placebo
• A key secondary endpoint succeeded: vibration perception threshold improved by 25% after 52 weeks of C-peptide therapy compared to baseline values
• Other electrophysiological variables and clinical neuropathy scores did not change

The vibration perception threshold improvement is clinically meaningful because impaired vibration perception is one of the earliest and most functionally significant signs of diabetic neuropathy. However, the failure of the primary endpoint (nerve conduction velocity) dampened enthusiasm for C-peptide replacement as a neuropathy treatment. Whether a longer treatment duration or different dosing regimen would produce broader neurological improvement remains unknown.

Earlier Neuropathy Evidence

Ekberg and colleagues (2008) provided earlier evidence for C-peptide's neuroprotective effects in a smaller trial showing that C-peptide replacement improved sensory nerve function in type 1 diabetes patients.^[8] The mechanisms of action involved correction of diabetes-induced reductions in endoneurial blood flow and Na+/K+-ATPase activity, plus modulation of neurotrophic factors.

Retinal Protection

Lee and colleagues (2023) demonstrated that systemic C-peptide supplementation ameliorated retinal neurodegeneration in a preclinical model by inhibiting VEGF-induced pathological changes.^[9] Diabetic retinopathy involves both vascular and neuronal degeneration in the retina, and VEGF overexpression drives many of the vascular abnormalities. C-peptide's ability to modulate VEGF signaling in the retina suggests a potential role in preventing the neuronal component of diabetic eye disease.

The Broader Complications Picture

Chen and colleagues (2023) published an updated review compiling evidence for C-peptide's biological activity across diabetic complications.^[10] The review summarized that C-peptide can bind cell membrane signaling molecules, activate downstream pathways, and exert anti-oxidative, anti-apoptotic, and anti-inflammatory effects. Intracellular signaling involves G-proteins and calcium-dependent pathways, leading to activation of endothelial nitric oxide synthase (eNOS), Na+/K+-ATPase, and transcription factors involved in cellular defense.

Evidence from animal and cell studies suggests C-peptide replacement can improve renal lesions, retinopathy, and peripheral neuropathy. The critical gap is that no successful C-peptide replacement therapy has been developed despite these positive preclinical signals. The Wahren 2016 trial, while showing vibration threshold improvement, failed its primary endpoint, and no subsequent trial has advanced the program.

C-Peptide in Precision Diabetes Medicine

Vinay and colleagues (2026) published the most current comprehensive review, arguing for C-peptide's expanding role in precision diabetes care.^[1] Their framework positions C-peptide not just as a diabetes-type classifier but as a continuous variable informing personalized treatment across the diabetes spectrum:

• Beta-cell reserve quantification: Serial C-peptide measurements track the trajectory of beta-cell decline, potentially identifying patients who would benefit from immunotherapy or beta-cell preservation strategies before complete failure
• Treatment response monitoring: Changes in C-peptide under therapy reflect whether a treatment is modifying the underlying disease process or merely managing symptoms
• Complication risk stratification: Residual C-peptide secretion in type 1 diabetes is associated with lower rates of hypoglycemia, diabetic ketoacidosis, and microvascular complications, suggesting that even small amounts of endogenous beta-cell function are clinically protective

The Standardization Problem

A persistent and unresolved limitation of C-peptide measurement is assay standardization. Different immunoassay platforms used by different laboratories can produce clinically meaningful differences in measured C-peptide values for the same patient sample.^[2]

The clinical consequences are direct: a diagnostic cutoff of 0.2 nmol/L for identifying severe beta-cell deficiency is widely used, but if two laboratories report different values for the same blood sample, the patient could be classified differently depending on where the test was run. International standardization efforts are ongoing but incomplete.

This is not a theoretical concern. In multicenter clinical trials using C-peptide as an endpoint (such as trials testing beta-cell preservation therapies), inter-laboratory variability introduces noise that can obscure treatment effects. Until C-peptide assays are standardized to the level of HbA1c or glucose measurement, the precision of C-peptide-based clinical decisions has an inherent ceiling.

What C-Peptide Cannot Tell You

Acute insulin dynamics. Because C-peptide has a 30-minute half-life versus 4-5 minutes for insulin, it cannot capture the rapid pulsatile insulin secretion that characterizes normal beta-cell function. C-peptide integrates secretion over time rather than tracking moment-to-moment changes.

Insulin sensitivity. C-peptide measures beta-cell output, not how effectively that insulin works in target tissues. An elevated C-peptide could indicate insulin resistance (compensatory hypersecretion) or simply a well-functioning pancreas in the fed state. Context, including glucose levels and clinical presentation, is required for interpretation.

Exogenous insulin dosing. In patients receiving insulin therapy, C-peptide reflects only endogenous insulin production. This is actually an advantage for measuring residual beta-cell function in insulin-treated patients, but it provides no information about the adequacy or timing of the exogenous insulin regimen.

Renal function confounding. Because C-peptide is cleared by the kidneys, impaired renal function elevates C-peptide levels independent of beta-cell activity. In patients with diabetic nephropathy, C-peptide values must be interpreted in the context of estimated glomerular filtration rate (eGFR). For the copeptin biomarker, renal function similarly affects interpretation.

The Bottom Line

C-peptide is the most reliable clinical measure of pancreatic beta-cell function, released in equimolar amounts with insulin but with superior pharmacokinetics for measurement (longer half-life, no hepatic extraction). It differentiates diabetes types, guides treatment selection, and tracks beta-cell decline over time. Beyond its biomarker role, C-peptide has demonstrated biological activity in diabetic neuropathy (25% improvement in vibration perception in a 12-month trial) and retinal neurodegeneration (preclinical VEGF modulation). No C-peptide replacement therapy has been approved despite positive signals, and assay standardization remains an unresolved barrier to precision application.

Frequently Asked Questions

What does a C-peptide test measure?

A C-peptide test measures how much C-peptide is in the blood, which directly reflects how much insulin the pancreas is producing. C-peptide is released in a 1:1 ratio with insulin and has a half-life of approximately 30 minutes (versus 4-5 minutes for insulin), making it a more reliable indicator of beta-cell function. The test is used to differentiate diabetes types, monitor beta-cell decline, and assess residual insulin production in patients on insulin therapy.

What is a normal C-peptide level?

Normal fasting C-peptide levels typically range from 0.5 to 2.0 ng/mL (0.17-0.67 nmol/L), though reference ranges vary between laboratories due to assay standardization issues. A fasting C-peptide below 0.2 nmol/L (0.6 ng/mL) strongly suggests type 1 diabetes or severe beta-cell failure (Maddaloni et al., 2022). Levels above the normal range may indicate insulin resistance, insulinoma, or type 2 diabetes with compensatory hyperinsulinemia.

Can C-peptide tell the difference between type 1 and type 2 diabetes?

Yes, C-peptide is the primary biomarker used to differentiate diabetes types. Type 1 diabetes typically shows very low or undetectable C-peptide due to autoimmune beta-cell destruction, while type 2 diabetes usually shows normal or elevated levels reflecting insulin resistance with preserved beta-cell mass. The discriminatory power is strongest in established diabetes; at initial diagnosis, there can be overlap between types, particularly in adults (Maddaloni et al., 2022).

Does C-peptide have biological activity?

Evidence from animal studies and one 12-month clinical trial suggests C-peptide has biological activity beyond its role as a biomarker. Wahren et al. (2016) showed long-acting C-peptide improved vibration perception by 25% in type 1 diabetes patients with neuropathy, though the primary endpoint (nerve conduction velocity) was not met. C-peptide activates signaling pathways involving eNOS, Na+/K+-ATPase, and G-protein coupled receptors (Chen et al., 2023). No C-peptide therapy has been approved.

Why is C-peptide better than measuring insulin directly?

C-peptide is superior to direct insulin measurement for three reasons. First, its half-life is approximately 30 minutes versus 4-5 minutes for insulin, providing a more stable measurement. Second, unlike insulin, C-peptide is not extracted by the liver on first pass (approximately 50% of insulin is removed), so peripheral C-peptide levels more accurately reflect total beta-cell output. Third, C-peptide is not affected by exogenous insulin therapy, allowing measurement of residual beta-cell function in insulin-treated patients.

Can C-peptide help with diabetic neuropathy?

In a 12-month randomized trial, long-acting C-peptide replacement improved vibration perception threshold by 25% in type 1 diabetes patients with neuropathy compared to baseline, but did not improve sensory nerve conduction velocity or clinical neuropathy scores (Wahren et al., 2016). Earlier studies showed C-peptide improved endoneurial blood flow and Na+/K+-ATPase activity in nerves. No C-peptide therapy for neuropathy has been approved or further developed clinically.